Value
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.1 |
| P/S | 6.7 |
| EV/EBITDA | 5.7 |
| Fwd P/E | 7.2 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 17.5x
- ▸PEG: 0.08
RYAN · Why this verdict
Why Ryan Specialty Holdings (RYAN) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Ryan Specialty's exceptional free cash flow conversion and strong growth in the specialty insurance market present a compelling long-term story, but near-term technicals and concentrated exposure to the E&S market demand caution.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Ryan Specialty converts 547% of net income into free cash flow, a remarkable figure that signals earnings quality well above typical insurance intermediaries and provides financial flexibility for growth investments. Quality breakdown | Free cash flow conversion remains above 200% of net income over the next four quarters, supporting dividend coverage and balance sheet health. | →Stable |
| CounterExtremely high free cash flow relative to net income can reflect timing differences or accounting items rather than structural superiority, and may normalize sharply in a down-cycle. | ||
With a PEG ratio of 0.08 and strong earnings growth, the market appears to be significantly underpricing Ryan Specialty's growth trajectory relative to peers in the specialty insurance space. Valuation breakdown | Revenue and earnings growth outpace the broader insurance industry over the next 12 months with earnings growth remaining above 10%. | →Stable |
| CounterA PEG ratio this low often signals the market doubts the sustainability of growth, particularly given an inconsistent recent earnings record including one miss and one inline result. | ||
Approximately 78% of revenue is concentrated in the E&S (excess and surplus) market, meaning a regulatory shift or competitive entry into specialty lines could materially impair revenue without diversification protection. Bear case | E&S market share remains above 70% while overall revenue grows, suggesting concentration is a feature rather than a vulnerability. | ↓Deteriorating |
| CounterE&S markets historically expand during periods of dislocation and tighten in soft markets; a reversal in the E&S cycle could compress Ryan Specialty's volumes and margins simultaneously. | ||
Despite a confirmed downtrend with the 200-day moving average declining at 8.4% per month, MACD is improving and RSI stands at 62, suggesting the worst of the selling pressure may be abating. Momentum breakdown | Price rises above the 200-day moving average and the death cross resolves within 12 months. | ↓Deteriorating |
| CounterThe asymmetry ratio of 0.62 means potential downside at 13.2% is more than double the upside of 8.2%, making premature entry expensive if the recovery stalls. | ||
Ryan Specialty converts 547% of net income into free cash flow, a remarkable figure that signals earnings quality well above typical insurance intermediaries and provides financial flexibility for growth investments.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 200% of net income over the next four quarters, supporting dividend coverage and balance sheet health.
CounterExtremely high free cash flow relative to net income can reflect timing differences or accounting items rather than structural superiority, and may normalize sharply in a down-cycle.
With a PEG ratio of 0.08 and strong earnings growth, the market appears to be significantly underpricing Ryan Specialty's growth trajectory relative to peers in the specialty insurance space.
→StableValuation breakdown
- Expectation
- Revenue and earnings growth outpace the broader insurance industry over the next 12 months with earnings growth remaining above 10%.
CounterA PEG ratio this low often signals the market doubts the sustainability of growth, particularly given an inconsistent recent earnings record including one miss and one inline result.
Approximately 78% of revenue is concentrated in the E&S (excess and surplus) market, meaning a regulatory shift or competitive entry into specialty lines could materially impair revenue without diversification protection.
↓DeterioratingBear case
- Expectation
- E&S market share remains above 70% while overall revenue grows, suggesting concentration is a feature rather than a vulnerability.
CounterE&S markets historically expand during periods of dislocation and tighten in soft markets; a reversal in the E&S cycle could compress Ryan Specialty's volumes and margins simultaneously.
Despite a confirmed downtrend with the 200-day moving average declining at 8.4% per month, MACD is improving and RSI stands at 62, suggesting the worst of the selling pressure may be abating.
↓DeterioratingMomentum breakdown
- Expectation
- Price rises above the 200-day moving average and the death cross resolves within 12 months.
CounterThe asymmetry ratio of 0.62 means potential downside at 13.2% is more than double the upside of 8.2%, making premature entry expensive if the recovery stalls.
Per-dimension breakdown
Quality
5.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 7.4 |
| ROA | 2.3 |
| Gross margin | 4.3 |
| Op margin | 10.0 |
| Net margin | 1.6 |
| Current ratio | 4.0 |
| FCF quality | 10.0 |
| Moat | 6.1 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 590% FCF/NI
- ▸Strong Piotroski F-Score: 7/9
Growth
7.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.3 |
| EPS growth | 10.0 |
Momentum
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 5.0 |
| Volume | 4.7 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 7.7 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 20%
Insider
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 6.8 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider buying — $4,182,084 (0.025% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.3 |
| quality rank | 4.0 |
| growth rank | 3.1 |
Technical
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.2 |
| support resistance | 6.4 |
| 52w position | 4.0 |
Risk (lower is worse)
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.7 |
| days to cover | 4.3 |
| volatility | 4.4 |
| put call | 7.7 |
| implied vol | 2.4 |
| beta | 9.6 |
| debt equity | 1.3 |
- ▸High IV: 66%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 5.5 |
| dividend safety | 6.0 |
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:5.0>=4.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:56d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:1.2<1.5@spot
Warning (1)
- MOMENTUM:5.0<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
1.25
Upside
+8.1%
Downside
6.5%
Sizing output
AVOID
SetupRange Bound — RSI 54 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Insider at 7.6) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:1.2<1.5@spot) reinforce the read. Current asymmetry R:R is 1.25 — supplementary context, not the trigger for this path.
The strongest dimensions are Insider at 7.6, Growth at 7.2, and Sentiment at 6.8; the weakest are Peer rank at 2.1, Risk (lower is worse) at 4.8, and Momentum at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.25 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Fcf Conversion Strength
Trip ifFree cash flow falls below 100% of net income for at least 2 consecutive quarters.
- P2Growth Profile Premium
Trip ifEarnings growth rate drops below 5% year-over-year for at least 2 of the next 4 quarters.
- P3Es Market Concentration Risk
Trip ifE&S market revenue share declines below 65% or total revenue falls more than 10% below prior-year levels.
- P4Technical Recovery Watch
Trip ifPrice drops below $32, more than 9% below the current $35.34, confirming trend failure.